论文部分内容阅读
日本儿童癌(?)白血病研究小组为了提高儿童急性淋巴细胞白血病(ALL)的治愈率,自1981年1月至1983年12月共收治131例标准危险组初治ALL,以JCCLSG-S811方案进行治疗。可供分析者119例,经强的松(PRD)加长春新碱(VCR)或长春碱酰胺治疗115例(96.6%)达到完全缓解(CR)。给18Gy头颅放疗和3次MTX鞘内注射作为预防中枢神经系统(CNS)白血病治疗后,将病人随机分为两组。甲组应用中剂量MTX+6MP间歇维持化疗,即VCR2mg/M~2(?)+Ppd120mg/M~2/日×5天(口服)十6MP175mg/M~2/日×5天(口服),与MTX225mg/M~2(?),每两周交替应用。乙组应用小剂量MTX十6MP连续维持化疗,即6MP50mg/M~2/日+MTX20mg/M~2
In order to improve the cure rate of childhood acute lymphoblastic leukemia (ALL), the Japanese Children’s Cancer (?) Leukemia Research Group has treated 131 cases of newly diagnosed ALL from the standard risk group from January 1981 to December 1983, using the JCCLSG-S811 protocol. treatment. Analysts in 119 patients were treated with prednisone (PRD) plus vincristine (VCR) or vinblastine amide for 115 patients (96.6%) to achieve complete remission (CR). After 18 Gy cranial radiotherapy and 3 MTX intrathecal injections as prevention of CNS leukemia treatment, the patients were randomly divided into two groups. In Group A, MTX+6MP was used to maintain intermittent chemotherapy, ie, VCR 2mg/M~2(?)+Ppd120mg/M~2/day x 5 days (oral), 10 6MP175mg/M~2/day x 5 days (oral), With MTX225mg/M~2(?), alternating application every two weeks. Group B was treated with low-dose MTX-6MP continuously, ie 6MP50mg/M~2/day+MTX20mg/M~2